PRINCETON, N.J., May 31, 2020 /PRNewswire/ -- Taiho Oncology, Inc. today announced efficacy and safety results of an interim analysis of FOENIX-CCA2, a single-arm multicenter Phase 2 study evaluating futibatinib (TAS-120) in patients with intrahepatic cholangiocarcinoma (iCCA) harboring...
from PR Newswire: https://ift.tt/2Am9n98
No comments:
Post a Comment